Characteristics of 118 patients in the TKI analysis
| All (n=118) | Deleterious DDR (n=24) | Wild type/VUS DDR (n=94) | |
| Age at start of treatment (years), median (range) | 60 (34–86) | 63 (34–74) | 60 (37–86) |
| Gender (male) | 87 (74%) | 20 (83%) | 67 (71%) |
| Nephrectomy | 110 (93%) | 23 (96%) | 87 (92%) |
| IMDC risk score at starting VEGF-TKI therapy | |||
| Favorable | 32 (29%) | 5 (25%) | 27 (30%) |
| Intermediate | 63 (58%) | 11 (55%) | 52 (59 |
| Poor | 14 (13%) | 4 (20%) | 10 (11%) |
| VEGF-TKI agent | |||
| Sunitinib | 73 (62%) | 12 (50%) | 61 (65%) |
| Pazopanib | 42 (36%) | 11 (46%) | 31 (33%) |
| Tivozanib | 1 (1%) | 0 | 1 (1%) |
| Axitinib | 1 (1%) | 0 | 1 (1%) |
| Sorafenib | 1 (1%) | 1 (4%) | 0 |
| Line of TKI therapy | |||
| First line | 118 (100%) | 24 (100%) | 94 (100%) |
DDR, DNA damage repair; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VUS, variants of unknown significance.